The ELIOS study (NCT03239340) is a phase II, open-label, single-arm trial designed to evaluate the efficacy, safety and resistance mechanisms to osimertinib when administered as first-line therapy in patients with locally advanced or metastatic EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.